CORR® Tumor Board: Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.
作者信息
Anderson Megan E, Wu Jim S, Vargas Sara O
机构信息
M. E. Anderson, Orthopaedic Oncology Surgeon, Beth Israel Deaconess Medical Center and Boston Children's Hospital, Boston, MA, USA J. S. Wu, Musculoskeletal Radiologist, Beth Israel Deaconess Medical Center, Boston, MA, USA S. O. Vargas, Staff Pathologist, Boston Children's Hospital, Boston, MA, USA.
出版信息
Clin Orthop Relat Res. 2018 Jul;476(7):1396-1399. doi: 10.1097/CORR.0000000000000349.
Abstract
摘要
相似文献
1
CORR® Tumor Board: Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.CORR®肿瘤专家会诊：微转移药物筛选平台显示骨肉瘤细胞系对MAP化疗有不同反应
Clin Orthop Relat Res. 2018 Jul;476(7):1396-1399. doi: 10.1097/CORR.0000000000000349.
2
CORR Insights®: Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.CORR见解®：微转移药物筛选平台显示骨肉瘤细胞系对MAP化疗的反应具有异质性。
Clin Orthop Relat Res. 2018 Jul;476(7):1412-1414. doi: 10.1097/01.blo.0000540061.16243.f9.
3
Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.微转移药物筛选平台显示骨肉瘤细胞系对 MAP 化疗的异质性反应。
Clin Orthop Relat Res. 2018 Jul;476(7):1400-1411. doi: 10.1007/s11999.0000000000000059.
4
CORR® Tumor Board: Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma?CORR®肿瘤病例讨论会：肿瘤标本中的微小血管侵犯与高级别局限性骨肉瘤患者的预后较差是否相关？
Clin Orthop Relat Res. 2020 Jun;478(6):1186-1189. doi: 10.1097/CORR.0000000000001208.
5
CORR (®) Tumor Board: Does Microwave Ablation of the Tumor Edge Allow for Joint-sparing Surgery in Patients with Osteosarcoma of the Proximal Tibia?CORR（®）肿瘤病例讨论会：对胫骨近端骨肉瘤患者进行肿瘤边缘微波消融是否能实现保关节手术？
Clin Orthop Relat Res. 2016 May;474(5):1110-2. doi: 10.1007/s11999-015-4660-8. Epub 2015 Dec 10.
6
Current concepts on the molecular biology of osteosarcoma.骨肉瘤分子生物学的当前概念
Cancer Treat Res. 2009;152:467-78. doi: 10.1007/978-1-4419-0284-9_27.
7
18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.18F-FDG PET的最大标准摄取值（SUVmax）与骨肉瘤对新辅助化疗的组织学反应相关：原位大鼠模型的临床前评估
J Nucl Med. 2009 Sep;50(9):1533-40. doi: 10.2967/jnumed.109.062356. Epub 2009 Aug 18.
8
Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response.骨肉瘤中 microRNA 谱作为异环磷酰胺反应的预测工具。
Int J Cancer. 2011 Aug 1;129(3):680-90. doi: 10.1002/ijc.25715. Epub 2010 Nov 23.
9
Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.临床前证据表明，TRAIL 在尤文肉瘤和骨肉瘤治疗中的应用可抑制肿瘤生长、防止溶骨性骨破坏，并提高动物生存率。
Clin Cancer Res. 2010 Apr 15;16(8):2363-74. doi: 10.1158/1078-0432.CCR-09-1779. Epub 2010 Apr 6.
10
CORR Insights®: Quantitative Primary Tumor Indocyanine Green Measurements Predict Osteosarcoma Metastatic Lung Burden in a Mouse Model.CORR 见解®：定量原发性肿瘤吲哚菁绿测量可预测小鼠模型中骨肉瘤的肺转移负担
Clin Orthop Relat Res. 2018 Mar;476(3):488-489. doi: 10.1007/s11999.0000000000000136.
本文引用的文献
1
Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.微转移药物筛选平台显示骨肉瘤细胞系对 MAP 化疗的异质性反应。
Clin Orthop Relat Res. 2018 Jul;476(7):1400-1411. doi: 10.1007/s11999.0000000000000059.
2
Osteosarcoma: Accelerating Progress Makes for a Hopeful Future.骨肉瘤：加速进展铸就充满希望的未来。
Front Oncol. 2018 Jan 26;8:4. doi: 10.3389/fonc.2018.00004. eCollection 2018.
3
An Overview of the Changing Landscape of Treatment for Advanced Melanoma.晚期黑色素瘤治疗格局的变化概述
Pharmacotherapy. 2017 Mar;37(3):319-333. doi: 10.1002/phar.1895. Epub 2017 Feb 17.
4
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
5
Magnetic resonance imaging of osteosarcoma using a bis(alendronate)-based bone-targeted contrast agent.使用基于双膦酸盐的骨靶向造影剂对骨肉瘤进行磁共振成像。
Biomed Pharmacother. 2016 Dec;84:423-429. doi: 10.1016/j.biopha.2016.09.061. Epub 2016 Sep 25.
6
Addressing intra-tumoral heterogeneity and therapy resistance.解决肿瘤内异质性和治疗抗性问题。
Oncotarget. 2016 Nov 1;7(44):72322-72342. doi: 10.18632/oncotarget.11875.
7
Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling.儿科肿瘤学专家对为进行基因组分析而对复发或难治性疾病儿童实体瘤进行活检的看法。
Ann Surg Oncol. 2016 Dec;23(Suppl 5):990-997. doi: 10.1245/s10434-016-5453-3. Epub 2016 Jul 26.
8
Intratumoral Heterogeneity of the Epigenome.表观基因组的肿瘤内异质性
Cancer Cell. 2016 Apr 11;29(4):440-451. doi: 10.1016/j.ccell.2016.03.009.
9
CXCR4-targeted near-infrared imaging allows detection of orthotopic and metastatic human osteosarcoma in a mouse model.靶向CXCR4的近红外成像可在小鼠模型中检测原位和转移性人骨肉瘤。
Sci Rep. 2015 Oct 16;5:15244. doi: 10.1038/srep15244.
10
The challenges posed by cancer heterogeneity.癌症异质性带来的挑战。
Nat Biotechnol. 2012 Jul 10;30(7):604-10. doi: 10.1038/nbt.2294.
Zotero 插件